Affordable Access

Access to the full text

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

Authors
  • Stark, Felicity C.
  • Agbayani, Gerard
  • Sandhu, Jagdeep K.
  • Akache, Bassel
  • McPherson, Charis
  • Deschatelets, Lise
  • Dudani, Renu
  • Hewitt, Melissa
  • Jia, Yimei
  • Krishnan, Lakshmi
  • McCluskie, Michael J.
Type
Published Article
Journal
Biomedicines
Publisher
MDPI
Publication Date
Nov 23, 2019
Volume
7
Issue
4
Identifiers
DOI: 10.3390/biomedicines7040091
PMID: 31771150
PMCID: PMC6966619
Source
PubMed Central
Keywords
License
Green

Abstract

Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed formulation which offers many advantages, including reduced loss of antigen, consistency of batch-to-batch production as well as providing the option to formulate the vaccine immediately before use, which is beneficial for next generation cancer therapy platforms that include patient specific neo-antigens or for use with antigens that are less stable. Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA–OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. Furthermore, archaeosome vaccine formulations combined with anti-CTLA-4 and anti-PD-1 therapy, induced OVA-CD8+ T cells within the tumor and immunohistochemical analysis revealed the presence of CD8+ T cells associated with dying or dead tumor cells as well as within or around tumor blood vessels. Overall, archaeosomes constitute an attractive option for use with combinatorial checkpoint inhibitor cancer therapy platforms.

Report this publication

Statistics

Seen <100 times